Novartis phase 2 product improves symptoms in patients with plaque psoriasis

Data from three phase 2 trials presented at the annual European Academy of Dermatology and Venereology Congress, indicate that secukinumab (AIN457, Novartis) improves the symptoms of moderate-to-severe plaque psoriasis quickly, and in most patients.  Secukinumab suppresses inflammation in psoriasis by binding and neutralizing … Continue reading

New melanoma drug may not be funded by NHS – in spite of improved survival in some patients

The National Institute for Health and Clinical Excellence (NICE) in the UK issued new draft guidance recommending against the use of ipilumab (Yervoy, Bristol-Myers Squibb) for advanced malignant melanoma in patients who have previously received chemotherapy. The rationale for the preliminary … Continue reading